Mitochondrial encephalomyopathy and retinoblastoma explained by compound heterozygosity of SUCLA2 point mutation and 13q14 deletion

• Published in: European journal of human genetics : EJHG Vol. 23; no. 3; pp. 325 - 330
• Main Authors: Matilainen, Sanna, Isohanni, Pirjo, Euro, Liliya, Lönnqvist, Tuula, Pihko, Helena, Kivelä, Tero, Knuutila, Sakari, Suomalainen, Anu
• Format: Journal Article
• Language: English
• Published: England Nature Publishing Group 01-03-2015
• Subjects: Aciduria; Adolescent; Age; Binding sites; Biochemistry; Brain - pathology; Brain research; Children; Chromosome Deletion; Chromosomes, Human, Pair 13; Clonal deletion; Comparative Genomic Hybridization; Deoxyribonucleic acid; DNA; E coli; Enzymes; Fatal Outcome; Gene deletion; Gene Frequency; Genes; Genetics; Heredity; Heterozygosity; Heterozygote; Homology; Hospitals; Humans; Infant; Kinases; Magnetic Resonance Imaging; Male; Mitochondrial DNA; Mitochondrial Encephalomyopathies - complications; Mitochondrial Encephalomyopathies - diagnosis; Mitochondrial Encephalomyopathies - genetics; Models, Molecular; Motor ability; Musculoskeletal system; Mutation; Neurology; NMR; Nuclear magnetic resonance; Patients; Pedigree; Phosphorylation; Point Mutation; Protein Conformation; Retinoblastoma; Retinoblastoma - complications; Retinoblastoma - diagnosis; Retinoblastoma - genetics; Retinoblastoma protein; Sequence Analysis, DNA; Structure-Activity Relationship; Structure-function relationships; Succinate-CoA Ligases - chemistry; Succinate-CoA Ligases - genetics; Succinyl-CoA; Tricarboxylic acid cycle; Urine; Finland
• ISSN: 1018-4813; 1476-5438
• DOI: 10.1038/ejhg.2014.128

Mutations in SUCLA2, encoding the ß-subunit of succinyl-CoA synthetase of Krebs cycle, are one cause of mitochondrial DNA depletion syndrome. Patients have been reported to have severe progressive childhood-onset encephalomyopathy, and methylmalonic aciduria, often leading to death in childhood. We studied two families, with children manifesting with slowly progressive mitochondrial encephalomyopathy, hearing impairment and transient methylmalonic aciduria, without mtDNA depletion. The other family also showed dominant inheritance of bilateral retinoblastoma, which coexisted with mitochondrial encephalomyopathy in one patient. We found a variant in SUCLA2 leading to Asp333Gly change, homozygous in one patient and compound heterozygous in one. The latter patient also carried a deletion of 13q14 of the other allele, discovered with molecular karyotyping. The deletion spanned both SUCLA2 and RB1 gene regions, leading to manifestation of both mitochondrial disease and retinoblastoma. We made a homology model for human succinyl-CoA synthetase and used it for structure-function analysis of all reported pathogenic mutations in SUCLA2. On the basis of our model, all previously described mutations were predicted to result in decreased amounts of incorrectly assembled protein or disruption of ADP phosphorylation, explaining the severe early lethal manifestations. However, the Asp333Gly change was predicted to reduce the activity of the otherwise functional enzyme. On the basis of our findings, SUCLA2 mutations should be analyzed in patients with slowly progressive encephalomyopathy, even in the absence of methylmalonic aciduria or mitochondrial DNA depletion. In addition, an encephalomyopathy in a patient with retinoblastoma suggests mutations affecting SUCLA2.